Ciprofloxacin
- Generic Name
- Ciprofloxacin
- Brand Names
- Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18FN3O3
- CAS Number
- 85721-33-1
- Unique Ingredient Identifier
- 5E8K9I0O4U
- Background
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
The first ciprofloxacin containing product was FDA approved on 22 October 1987.
- Indication
Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...
- Associated Conditions
- Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae
- Associated Therapies
- -
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Epicentre
- Registration Number
- NCT03431675
- Locations
- 🇳🇪
Madarounfa Health District, Madarounfa, Maradi, Niger
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 250
- Registration Number
- NCT03366207
- Locations
- 🇺🇸
Restore Clinical Research, Cary, North Carolina, United States
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 1395
- Registration Number
- NCT03357614
- Locations
- 🇱🇻
Medical Facility, Valmiera, Latvia
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 674
- Registration Number
- NCT03358576
- Locations
- 🇵🇱
Medical Facility, Bielsk Podlaski, Poland
Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 1671
- Registration Number
- NCT03354598
- Locations
- 🇺🇸
Medical Facility, South Jordan, Utah, United States
Otiprio Versus Ciprodex Tympanostomy Tube Outcomes
Phase 4
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Boston Medical Center
- Registration Number
- NCT03347461
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma
Early Phase 1
- Conditions
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT03326050
- Locations
- 🇪🇬
Asmaa Ahmed, Assiut, Egypt
Targeted AntiBiotics for Chronic Pulmonary Diseases
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2023-05-25
- Target Recruit Count
- 51
- Registration Number
- NCT03262142
- Locations
- 🇩🇰
Herlev and Gentofte Hospital, Hellerup, Copenhagen, Denmark
Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 1538
- Registration Number
- NCT03228108
- Locations
- 🇳🇱
Zuyderland Hospital, Sittard, Netherlands
🇳🇱Amphia Hospital, Breda, Netherlands
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
Evaluation of Innovative Tools in Development of Antibiotics
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 10
- Registration Number
- NCT03177720
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath